Tag: Drug
Source: Dr. Yi Chen (9/17/22) The purpose behind this complementary study is to potentially expand the treatment’s target patient population, noted an H.C. Wainwright & Co. report. ASLAN Pharmaceuticals Ltd. (ASLN:NASDAQ), to complement its in-progress TREK-AD dose-ranging eblasakimab trial for moderate to severe atopic dermatitis (eczema), plans a second study, TREK-DX, in the subpopulation of patients […]
On Jan. 14, AbbVie‘s (NYSE:ABBV) Rinvoq received approval from the U.S. Food and Drug Administration (FDA) to treat adults and children at least 12 years old with moderate-to-severe atopic dermatitis (eczema) whose condition didn’t respond to other medicines. What led the FDA to approve Rinvoq for its third indication? And how much of a boost […]